• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

In­di­vid­u­al­ized ther­a­pies: CBER di­rec­tor dis­cuss­es chal­lenges, reg­u­la­to­ry ap­proach

6 years ago
FDA+

New study sug­gests it costs $1.3B in R&D in­vest­ment to bring a drug to mar­ket. How did it get there?

6 years ago
R&D

Amu­nix grabs $73M from Fra­zier, Omega to fu­el shift to T cell en­gagers

6 years ago
R&D

Add Take­da and Al­ny­lam to the menu of glob­al drug­mak­ers look­ing to stymie the coro­n­avirus epi­dem­ic

6 years ago
R&D
Pharma

As costs con­tin­ue to soar ever high­er, As­traZeneca sees new HQ stick­er price gy­rate to $1.28B

6 years ago
Pharma

Hear hear! Ear gene ther­a­py play­er Ak­ou­os draws $105M in fresh cap­i­tal

6 years ago
Financing
Startups

Boast­ing new dis­cov­er­ies from Xtan­di, Er­lea­da in­ven­tors, ORIC pitch­es $86M IPO on can­cer drugs tar­get­ed at re­sis­tance

6 years ago
R&D

$7.5B in emer­gency con­gres­sion­al coro­n­avirus prep; Sick­le cell biotech sets terms for IPO

6 years ago
News Briefing

Fail­ure-prone Unum cuts jobs, los­es sci­en­tif­ic chief, and changes fo­cus yet again

6 years ago
R&D
Cell/Gene Tx

Bio­gen’s ear­ly R&D chief ex­its for ARCH and Be­zos-backed an­ti-ag­ing biotech

6 years ago
R&D

With one ri­val down, No­var­tis-part­nered biotech scores $100M round to fund mid-stage tri­als of fi­bro­sis drug

6 years ago
Financing

'Un­heard-of speed­s': Trump, new­ly warmed up to bio­phar­ma, prais­es in­dus­try's coro­n­avirus re­sponse at White House ...

6 years ago
Coronavirus

In record-set­ting set­tle­ment, No­var­tis’ San­doz unit ad­mits guilt in con­spir­a­cy to fix prices

6 years ago
R&D

Hap­py alone Qi­a­gen changes course af­ter Ther­mo Fish­er of­fers to buy it in $11.5B deal

6 years ago
Deals

Ver­tex, Seat­tle Ge­net­ics, Alpine with­draw from in­vestor con­fer­ence as biotechs brace for coro­n­avirus

6 years ago
People
Coronavirus

End­ing a gru­el­ing 10-year drought, Sanofi fi­nal­ly wins an OK for an in-house can­cer drug

6 years ago
R&D

No­var­tis re­it­er­ates its faith in Eylea ri­val Beovu; An­ti-NGF drug from Lil­ly, Pfiz­er is ac­cept­ed for FDA re­view

6 years ago
News Briefing

Karyopharm spot­lights PhI­II re­sults af­ter con­tro­ver­sial FDA ap­proval

6 years ago
R&D
Pharma

Mer­ck clears PFS end­point in con­fir­ma­to­ry tri­al for Keytru­da in clas­si­cal Hodgkin lym­phoma

6 years ago
R&D

Cer­tain GSK an­tibi­ot­ic brands are up for sale — re­port

6 years ago
R&D

As US di­als up coro­n­avirus re­sponse, BIO taps Vir's George Scan­gos to head com­mit­tee co­or­di­nat­ing in­dus­try ef­forts

6 years ago
People
Coronavirus

In pos­si­ble sign of things to come, Daniel O’Day’s new-look Gilead bets $4.9B on can­cer biotech

6 years ago
Deals

Mor­phoSys’ off-the-shelf ri­val to CAR-T ap­proach­es fin­ish line with a speedy re­view

6 years ago
R&D

Wood­ford who? TCR-fo­cused Im­muno­core sol­diers on with $130M+ B round

6 years ago
Financing
Cell/Gene Tx
First page Previous page 848849850851852853854 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.